and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte ...
Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...
This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...
Copyright held by the owner/author(s).
NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
A recent study led by Associate Professor Takuya Yamamoto and Researcher May Nakajima-Koyama has revealed that maintaining a delicate balance between interferon-gamma (IFN-γ) and extracellular ...
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
10 February 2025, St Andrews, Scotland: The R&A has announced the qualification pathways for The 153 rd Open at Royal Portrush, taking place July 13-20, 2025. The Open is one of the world’s greatest ...
This important study identifies a new key factor in orchestrating the process of glial wrapping of axons in Drosophila wandering larvae. The evidence supporting the claims of the authors is convincing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback